Answers are grounded in this paper and cite their sources.
Examines smoking's influence on lung function in sarcoidosis patients, suggesting limited impact.
Rationale: Sarcoidosis is classified as interstitial lung disease (ILD) and potentially restrictive, however airway obstruction is more common when compared to other ILDs. Smoking habit is well known independent risk factor for airway obstruction and was regarded as protective against sarcoidosis. The aim of study: to check the prevalence of smoking and its influence on lung function tests in the large group of sarcoidosis patients. Material and methods: Lung function data (spirometry, plethysmography, static lung compliance, and single breath DLCO) of 1260 consecutive patients with sarcoidosis (633 f, 627 m) were analyzed using GLI 2012, ERS 1993 and Colebach's predicted values. Results: There were 334 (26.5%), 744 (59.0%), 167 (13.3%) and 15 (1.2%) patients in stages I, II, III and IV respectively. Airflow obstruction (FEV1/FVC below the LLN) was detected in 149 patients (11.8%), while restrictive pattern (low TLC) in 98 patients (7.8%). The median duration of smoking in 487 ever-smokers (38% of all patients, what is similar to the prevalence of smoking in Poland in age 45-60) was 10.0 years (range 1-50), median cumulative tobacco consumption 7.5 packyears (range 0.1-90.0). There were statistically significant differences between exposed and not exposed to tobacco smoke patients mainly in lung volumes and DLCO (probably not clinically important), but not in spirometric indices of airway obstruction (which are expected to be affected by smoking) except FEF75. Conclusions: The impact of smoking habit on lung function in our group of sarcoidosis patients was marginal. Smoking seems not to have any protective role against sarcoidosis as it was previously regarded.
No takes yet. Share an insight, caveat, or question.
Boros et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: